INTRODUCTION: Leptin, a protein produced by adipocytes, is an important signaling molecule in energy regulation and food intake. Many obese patients have leptin resistance associated with increased circulating leptin. Leptin receptor activation downregulates many regulatory genes, including STAT-3 and PAP 1. Certain cancers are associated with obesity, including breast, prostate, and colon. Recent studies have shown that leptin stimulates proliferation of human colon cancer in vitro. We hypothesized that leptin would have stimulatory effects on other human cancers. MATERIALS AND METHODS: Human cancer cell lines from esophagus (KYSE410 and 150), breast (ZR75-1 and MCF-7), prostate (DU145 and PC-3), and pancreas (PANC-1, Mia-PaCa) were cultured using standard techniques. Leptin (0.4 ng/ml and 4.0 ng/ml) was added for 24 h and 48 h. Cell growth was determined by MTT assay. Statistical analysis was performed using analysis of variance. RESULTS: Cancer cell lines demonstrated dose- and time-related responses to treatment. Leptin caused growth potentiation in breast, esophagus, and prostate cancer (P < 0.05). However, in both Mia-PaCa and PANC-1 pancreatic cancer cells, leptin inhibited growth (P < 0.05). This inhibitory effect peaked in PANC-1 at 48 h (78%). CONCLUSIONS: We have shown for the first time that human cancer cells exhibit differential responses to treatment with leptin, depending upon organ of derivation. Both leptin and leptin antagonism have potential efficacy in cancer therapy, based on cellular origin. Further studies are warranted and ongoing.
INTRODUCTION:Leptin, a protein produced by adipocytes, is an important signaling molecule in energy regulation and food intake. Many obesepatients have leptin resistance associated with increased circulating leptin. Leptin receptor activation downregulates many regulatory genes, including STAT-3 and PAP 1. Certain cancers are associated with obesity, including breast, prostate, and colon. Recent studies have shown that leptin stimulates proliferation of humancolon cancer in vitro. We hypothesized that leptin would have stimulatory effects on other humancancers. MATERIALS AND METHODS:Humancancer cell lines from esophagus (KYSE410 and 150), breast (ZR75-1 and MCF-7), prostate (DU145 and PC-3), and pancreas (PANC-1, Mia-PaCa) were cultured using standard techniques. Leptin (0.4 ng/ml and 4.0 ng/ml) was added for 24 h and 48 h. Cell growth was determined by MTT assay. Statistical analysis was performed using analysis of variance. RESULTS:Cancer cell lines demonstrated dose- and time-related responses to treatment. Leptin caused growth potentiation in breast, esophagus, and prostate cancer (P < 0.05). However, in both Mia-PaCa and PANC-1 pancreatic cancer cells, leptin inhibited growth (P < 0.05). This inhibitory effect peaked in PANC-1 at 48 h (78%). CONCLUSIONS: We have shown for the first time that humancancer cells exhibit differential responses to treatment with leptin, depending upon organ of derivation. Both leptin and leptin antagonism have potential efficacy in cancer therapy, based on cellular origin. Further studies are warranted and ongoing.
Authors: Dana M Niedowicz; Christa M Studzinski; Adam M Weidner; Thomas L Platt; Kristen N Kingry; Tina L Beckett; Annadora J Bruce-Keller; Jeffrey N Keller; M Paul Murphy Journal: Biochim Biophys Acta Date: 2012-12-26
Authors: Cher M Dallal; Louise A Brinton; Douglas C Bauer; Diana S M Buist; Jane A Cauley; Trisha F Hue; Andrea Lacroix; Jeffrey A Tice; Victoria M Chia; Roni Falk; Ruth Pfeiffer; Michael Pollak; Timothy D Veenstra; Xia Xu; James V Lacey Journal: Endocr Relat Cancer Date: 2013-02-18 Impact factor: 5.678